Serum Chromogranin A Marker Sensitivity Dependent on Primary Tumour Location: Presented at ENETS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Serum Chromogranin A Marker Sensitivity Dependent on Primary Tumour Location: Presented at ENETS

By Karen Dente, MD

BERLIN -- March 17, 2010 -- The biomarker chromogranin A (CgA) has varied sensitivity for neuroendocrine tumours (NETs) dependent on the primary tumour location and some other factors, according to a study presented at the 7th European Neuroendocrine Tumor Society Conference (ENETS).

“CgA has been widely used as a tumour marker for patients with NETs of the gastrointestinal tract,” said S. Nölting, MD, Department of Internal Medicine II, University of Munich, Munich, Germany. The goal of the study was to assess the sensitivity of the tumour marker in NETs of the gastroenteropancreatic system.

The retrospective study measured CgA levels in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. All patients showed up in this single-centre series between 2000 and 2009. CgA determination was made by a commercially available immunoradiometric assay with a cutoff of <98 ng/mL.

CgA levels showed a higher sensitivity in patients with midgut NET than patients with pancreatic NET (68% vs 54%). Independent of the primary location of the tumour, a higher CgA sensitivity was seen in patients who had liver metastases than in those without (63% vs 31% for pancreatic NETs, 77% vs 40% in midgut NETs).

The median CgA levels were considerably higher in patients who had liver metastases (n = 82) than those who did not (n = 28) (P < .0001).

Even higher median levels of CgA were found in patients with liver and extrahepatic metastases in bone, lung, or peritoneum (n = 29) than with metastases in lymph nodes and liver alone (n = 53) (P = .005).

The researchers concluded that the sensitivity of CgA depends on the assay used for determination of CgA, the threshold cutoff, the primary location of NET, and local disease versus distant metastasis.

[Presentation title: Serum Chromogranin A as Tumor Marker in Neuroendocrine Tumors. Abstract C70]




E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities